Research Topics
Genomes and Genes | Charles M RudinSummaryAffiliation: Johns Hopkins University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancerSridhar Mani
Department of Medicine, Section of Hematology Oncology, Cancer Research Center, University of Chicago, Chicago, Illinois 60637, USA
Clin Cancer Res 8:1042-8. 2002..Our study warrants further exploration of efficacy in a Phase II and/or Phase III clinical trial setting...- A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancerChristopher G Azzoli
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
J Thorac Oncol 2:638-44. 2007..We undertook this phase II study to measure postoperative drug delivery and toxicity of cisplatin plus docetaxel in patients with resected stage I-III non-small cell lung cancer... - Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancersP Seshidhar Reddy
Neotropix, Inc, 351 Phoenixville Pike, Malvern, PA 19355, USA
J Natl Cancer Inst 99:1623-33. 2007..However, the treatment of metastatic disease with oncolytic viruses has been challenging due to the inactivation of viruses by components of human blood and/or to inadequate tumor selectivity... 
Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancerNicholas W Choong
Section of Hematology Oncology, University of Chicago Medical Center, Chicago, IL 60615, USA
J Thorac Oncol 3:59-67. 2008....- Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103Charles M Rudin
Sidney Kimmel Comprehensive Cancer Center, David H Koch Cancer Research Building, Suite 544, 1550 Orleans St, Baltimore, MD 21231, USA
J Clin Oncol 26:870-6. 2008..bcl-2 has been implicated as a key factor in SCLC oncogenesis and chemotherapeutic resistance... 
Inhibition of TWIST1 Leads to Activation of Oncogene-Induced Senescence in Oncogene-Driven Non-Small Cell Lung CancerTimothy F Burns
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, David H Koch Cancer Research Building, Room 544, 1550 Orleans Street, Baltimore MD 21231
Mol Cancer Res 11:329-38. 2013..Together these findings suggest that silencing of TWIST1 in oncogene driver-dependent NSCLCs represents a novel and promising therapeutic strategy. Mol Cancer Res; 11(4); 329-38. ©2013 AACR...- Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancerCharles M Rudin
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
Nat Genet 44:1111-6. 2012..These data provide an in-depth view of the spectrum of genomic alterations in SCLC and identify several potential targets for therapeutic intervention... - VismodegibCharles M Rudin
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
Clin Cancer Res 18:3218-22. 2012..The mechanism of action, preclinical and clinical data, and potential utility in other disease contexts are reviewed here... - Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancerCharles M Rudin
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Cancer Research Building 2, Room 544, 1550 Orleans Street, Baltimore, MD 21231, USA
Clin Cancer Res 18:3163-9. 2012..The primary objectives of this phase IIa study included safety at the recommended phase II dose and preliminary, exploratory efficacy assessment in patients with recurrent and progressive SCLC after at least one prior therapy... - Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I studyCharles M Rudin
The University of Chicago, Chicago, Illinois, USA
Clin Cancer Res 10:7244-51. 2004..Liposomal formulation may promote better intratumoral AON delivery and inhibit degradation in vivo. We conducted the first clinical evaluation of this concept using a liposomal AON complementary to the c-raf-1 proto-oncogene (LErafAON)... - Lung cancer in never smokers: a call to actionCharles M Rudin
Johns Hopkins University, Baltimore, Maryland 21231, USA
Clin Cancer Res 15:5622-5. 2009..This CCR Focus summarizes recent data, identifies knowledge deficits, and suggests future research directions with regard to this critically important subset of lung cancer patients... - Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancerCharles M Rudin
University of Chicago, Illinois, USA
J Clin Oncol 22:1110-7. 2004..A dose-finding study was performed evaluating the combination of G3139, carboplatin, and etoposide in patients with previously untreated extensive stage SCLC... - Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449Charles M Rudin
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
N Engl J Med 361:1173-8. 2009.... - Beyond the scalpel: targeting hedgehog in skin cancer preventionCharles M Rudin
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, Maryland, USA
Cancer Prev Res (Phila) 3:1-3. 2010..This new study of cyclooxygenase inhibition, together with recent data on the efficacy of hedgehog pathway inhibition, offers new hope for patients at a high risk for basal cell cancer... - Novel systemic therapies for small cell lung cancerCharles M Rudin
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
J Natl Compr Canc Netw 6:315-22. 2008..Novel therapeutic approaches based on advances in understanding of the biology of SCLC have the potential to radically change the outlook for patients with this disease... - Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancerCharles M Rudin
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, David H Koch Cancer Research Building 2, 1550 Orleans St, Rm 544, Baltimore, MD 21231, USA
J Clin Oncol 29:1075-82. 2011..We conducted a phase I and randomized double-blind phase II study of pemetrexed with ABT-751 or placebo in patients with recurrent advanced or metastatic non-small-cell lung cancer (NSCLC)... - Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicityCharles M Rudin
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, David H Koch Cancer Research Building, Room 544, 1550 Orleans St, Baltimore, MD 21231, USA
J Clin Oncol 26:1119-27. 2008..To assess the pharmacogenomic and pharmacokinetic determinants of skin rash and diarrhea, the two primary dose-limiting toxicities of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib... - Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine featuresCharles M Rudin
Johns Hopkins University, Baltimore, Maryland, USA
Clin Cancer Res 17:888-95. 2011..We conducted a first-in-human, first-in-class phase I clinical trial of this agent in patients with cancers with neuroendocrine features, including small cell lung cancer... - Lung cancer in never smokers: molecular profiles and therapeutic implicationsCharles M Rudin
Johns Hopkins University School of Medicine, David H Koch Cancer Research Building, Room 544, 1550 Orleans Street, Baltimore, MD 21231, USA
Clin Cancer Res 15:5646-61. 2009..Focused analysis of molecular carcinogenesis in lung cancers in never smokers is needed, and may provide additional biologic insight with therapeutic implications for lung cancers in both ever smokers and never smokers... - Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancerChristine L Hann
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
Cancer Res 68:2321-8. 2008..Taken together, these data have specific implications for the clinical development of Bcl-2 inhibitors for SCLC and broader implications for the testing of novel anticancer strategies in relevant preclinical models... - Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycinDavid J VanderWeele
Committee on Cancer Biology, University of Chicago, Illinois, USA
Mol Cancer Ther 3:1605-13. 2004..These data provide insight into potentially synergistic combinations of anticancer therapies... - Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancerNicholas W Choong
Section of Hematology-Oncology and Phase II Network, University of Chicago Medical Center, Chicago, Illinois 60615, USA
J Thorac Oncol 1:245-51. 2006..CONCLUSION: Second-line treatment with temozolomide and irinotecan showed tolerable toxicities. The response rates, median survival times, and 1-year survival rates were comparable to other active NSCLC agents... - DNA cleavage and Trp53 differentially affect SINE transcriptionChristy R Hagan
Committee on Cancer Biology and Department of Medicine, University of Chicago, Chicago, IL, USA
Genes Chromosomes Cancer 46:248-60. 2007..Together these data support a model in which initial DNA damage can trigger genomic instability due to SINE activation, a response which may be amplified in cancer cells lacking functional TP53... - Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancerRosalyn A Juergens
Department of Oncology, Johns Hopkins University, Baltimore, Maryland 21231, USA
Cancer Discov 1:598-607. 2011.... - Management of small-cell lung cancer: incremental changes but hope for the futureChristine L Hann
Upper Aerodigestive Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
Oncology (Williston Park) 22:1486-92. 2008..The past 2 decades have been marked by an improved understanding of SCLC biology, and these discoveries are reflected in the number and diversity of novel therapies entering early-phase testing in this disease... - Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has comeMalcolm V Brock
Division of Thoracic Surgery, Department of Surgery, The Johns Hopkinds Medical Institutions, Baltimore, MD, USA
J Thorac Cardiovasc Surg 129:64-72. 2005..Although resection is not the standard of care in treating small cell lung cancer, new platinum drugs and modern staging have allowed the role of surgery to be reevaluated... - Mammalian target of rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rateDavid J VanderWeele
Committee on Cancer Biology, University of Chicago, Chicago, IL, USA
Mol Cancer Res 3:635-44. 2005..We conclude that mTOR activity can promote resistance through multiple mechanisms independent of maintained glycolytic rate... - Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumorsPatricia M LoRusso
Karmanos Cancer Institute, Detroit, Michigan Johns Hopkins University, Baltimore, Maryland, USA
Clin Cancer Res 17:2502-11. 2011..This phase I trial assessed GDC-0449 treatment in patients with solid tumors refractory to current therapies or for which no standard therapy existed... - A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancerJerome D Winegarden
The Department of Medicine, Section of Hematology and Oncology, University of Chicago Medical Center, University of Chicago Cancer Center and the Phase II Network, 5841 S Maryland Avenue MC2115, Chicago, IL 60637, USA
Lung Cancer 39:191-6. 2003..The predominance of myalgia in the absence of elevated serum cytokines suggests a non-inflammatory etiology of this toxicity... - Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancerJoelle Hillion
Hematology Division, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Mol Cancer Res 7:1803-12. 2009..Our findings suggest an important role for MMP-2 in transformation mediated by HMGA1 in large-cell, undifferentiated lung carcinoma and support the development of strategies to target this pathway in selected tumors... - Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I studyPhilip C Hoffman
Department of Medicine, The University of Chicago, 5841 S. Maryland Avenue, MC 2115, Chicago, IL 60637, USA
Lung Cancer 38:65-71. 2002..5 months. We conclude that the combination of carboplatin, vinorelbine, and radiotherapy is feasible at these doses. It may be a useful alternative for patients not able to tolerate cisplatin-based therapy... - A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitroVincent C Daniel
Department of Surgery, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
Cancer Res 69:3364-73. 2009..Such changes in gene expression may be a common feature of many cancer cell culture systems, with functional implications for the use of such models for preclinical drug development... - Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancerBlake T Aftab
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
Cancer Res 71:6764-72. 2011..Based on these observations, we have initiated a randomized phase II study comparing the efficacy of standard cytotoxic therapy with or without daily oral itraconazole in patients with recurrent metastatic NSCLC... - Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancerCharles M Rudin
Johns Hopkins University, Baltimore, Maryland
J Thorac Oncol 8:619-23. 2013..On the basis of these data, we performed an exploratory clinical study, assessing the efficacy of itraconazole with cytotoxic chemotherapy in the treatment of patients with advanced lung cancer... - Characterization of a full-length infectious cDNA clone and a GFP reporter derivative of the oncolytic picornavirus SVV-001John T Poirier
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA
J Gen Virol 93:2606-13. 2012..These infectious clones will be of substantial value in further characterizing the biology of this virus and as a backbone for the generation of additional oncolytic derivatives... - Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesisPhuoc T Tran
Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore, Maryland, United States of America
PLoS Genet 8:e1002650. 2012..Hence, TWIST1 is a critical regulator of cellular senescence programs, and the suppression of TWIST1 in human tumors may be an effective example of pro-senescence therapy... - Crizotinib in the treatment of non-small-cell lung cancerPatrick M Forde
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA
Expert Opin Pharmacother 13:1195-201. 2012..Crizotinib has demonstrated efficacy against ALK-rearranged NSCLC, and has potential for broader application in select subsets of lung cancer... - Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistanceCharles M Rudin
Department of Medicine and Committee on Cancer Biology, University of Chicago, Chicago, Illinois 60637, USA
Cancer Res 63:312-8. 2003..Inhibition of glutathione synthesis or modulation of glutathione stores in tumors that overexpress Bcl-2 may comprise a novel anticancer strategy... - Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecanFederico Innocenti
Department of Medicine, University of Chicago, 5841 S Maryland Ave, MC2115, Chicago, IL 60637, USA
J Clin Oncol 22:1382-8. 2004..UDP-glucuronosyltransferase 1A1 (UGT1A1) catalyzes the glucuronidation of the active metabolite SN-38. This study prospectively evaluated the association between the prevalence of severe toxicity and UGT1A1 genetic variation... - Lung cancer in never smokers: clinical epidemiology and environmental risk factorsJonathan M Samet
Johns Hopkins University, Baltimore, Maryland, USA
Clin Cancer Res 15:5626-45. 2009..However, a large fraction of lung cancers occurring in never smokers cannot be definitively associated with established environmental risk factors, highlighting the need for additional epidemiologic research in this area... - A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonistsVenugopal Chenna
Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
Mol Cancer Ther 11:165-73. 2012..No demonstrable hematologic or biochemical abnormalities were observed with NanoHHI administration. NanoHHI should be amenable to clinical translation in settings where tumors acquire mutational resistance to current Smo antagonists... - Notch signaling contributes to lung cancer clonogenic capacity in vitro but may be circumvented in tumorigenesis in vivoJoyce Osanyingbemi-Obidi
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
Mol Cancer Res 9:1746-54. 2011..Distinct Notch family members may have different and potentially opposing activities in oncogenesis, and targeted inhibition of individual Notch family members may be a more effective anticancer strategy than global pathway suppression... - Svf1 inhibits reactive oxygen species generation and promotes survival under conditions of oxidative stress in Saccharomyces cerevisiaeJennifer L Brace
The Committee on Cancer Biology, University of Chicago, Chicago, IL 60637, USA
Yeast 22:641-52. 2005..Our data are consistent with previous observations suggesting a key role of oxidative stress response in mammalian apoptotic regulation and validate the use of S. cerevisiae as a model for studying programmed cell death... - SVF1 regulates cell survival by affecting sphingolipid metabolism in Saccharomyces cerevisiaeJennifer L Brace
Johns Hopkins University, Baltimore, Maryland 21231, USA
Genetics 175:65-76. 2007..Together, these data suggest that compartmentalized generation of distinct intracellular subsets of sphingoid bases may be critical for activation of signaling pathways that control cell growth and survival... - Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancerChristine L Hann
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University Cancer Research, Building 2, Baltimore, MD 21231, USA
Trends Mol Med 13:150-7. 2007.... - ALK-targeted therapy for lung cancer: ready for prime timeHatim Husain
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
Oncology (Williston Park) 25:597-601. 2011..Taken together, these data describe a trajectory of research progress from basic discovery science to real-world implementation that should serve as a model for future integration of preclinical and clinical therapeutic research... - Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancerRebekah L Zinn
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University School of Medicine, 1550 Orleans Street, Baltimore, MD, USA
Mol Cancer 12:16. 2013..Chemotherapy and targeted therapies, including the Bcl-2 inhibitor ABT-737, may induce tumor cell autophagy. Autophagy can promote survival of cancer cells under stress and comprise a pathway of escape from cytotoxic therapies... - Bcl-x(L) complements Saccharomyces cerevisiae genes that facilitate the switch from glycolytic to oxidative metabolismMatthew G Vander Heiden
Department of Medicine, The University of Chicago, Chicago, Illinois 60637, USA
J Biol Chem 277:44870-6. 2002..Further characterization of the genes identified in this screen may enhance our understanding of Bcl-x(L) function in mammalian cells, and of cell survival pathways in general... - Bcl-x(L) and Akt cooperate to promote leukemogenesis in vivoRobyn Karnauskas
Department of Medicine, University of Chicago, IL 60637, USA
Oncogene 22:688-98. 2003..These results implicate activated Akt and growth-factor independence in leukemogenic transformation, and demonstrate the potential for in vivo analysis of genetic determinants of leukemogenesis... - Mobile genetic element activation and genotoxic cancer therapy: potential clinical implicationsChristy R Hagan
Committee on Cancer Biology and Department of Medicine, University of Chicago, 5841 Aouth Maryland Avenue, Chicago, IL 60637, USA
Am J Pharmacogenomics 2:25-35. 2002..Understanding the cellular responses to genotoxic stress may permit the development of a means of predicting the risks and preventing the development of secondary malignancy following cancer therapy... - Human Alu element retrotransposition induced by genotoxic stressChristy R Hagan
Biological Sciences Division and Committee on Cancer Biology, University of Chicago, Chicago, Illinois 60637, USA
Nat Genet 35:219-20. 2003..We report that Alu retrotransposition can be induced in mouse cells by exposure to the topoisomerase II inhibitor etoposide and is mediated in trans by endogenous mouse long interspersed elements (LINEs)... - Geographic proximity and racial disparities in cancer clinical trial participationNorma F Kanarek
Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
J Natl Compr Canc Netw 8:1343-51. 2010..Clinical trial accruals are not uniform across age, sex, race, place of residence, cancer site, or trial type, underscoring that cancer centers must better understand their source patients to enhance clinical trial participation... - Skin deep and deeper: multiple pathways in basal cell carcinogenesisCraig D Peacock
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, David H Koch Cancer Research Building, Room 546, 1550 Orleans Street, Baltimore, MD 21231, USA
Cancer Prev Res (Phila) 3:1213-6. 2010..both raise questions about the cell of origin for basal cell cancers and define additional putative therapeutic and preventive targets for this disease... - An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasiaCharles M Rudin
Medical Center, University of Chicago, 5841 S Maryland Ave, MC2115, Chicago, IL 60637, USA
J Clin Oncol 21:4546-52. 2003..The current study sought to establish the feasibility and activity of ONYX-015 administered topically as a mouthwash to patients with clinically apparent and histologically dysplastic lesions of the oral mucosa... - The future of epigenetic therapy in solid tumours-lessons from the pastNilofer Azad
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, CRB1, 1650 Orleans Street Suite 541, Baltimore, MD 21287, USA
Nat Rev Clin Oncol 10:256-66. 2013..If so, optimal use of these known agents might also pave the way for the introduction of other agents that target the epigenome... - Hedgehog pathway inhibition radiosensitizes non-small cell lung cancersJing Zeng
Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland
Int J Radiat Oncol Biol Phys 86:143-9. 2013..Whether Hedgehog inhibition can affect radiation efficacy in vivo has not been reported... - Poly(β-amino ester) Nanoparticle Delivery of TP53 Has Activity against Small Cell Lung Cancer In Vitro and In VivoChandrashekhar D Kamat
Corresponding Author Christine L Hann, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Cancer Research Building 2, Room 553, 1550 Orleans Street, Baltimore, MD 21287
Mol Cancer Ther 12:405-15. 2013..This technology may have general applicability as a novel anticancer strategy based on restoration of tumor suppressor gene function. Mol Cancer Ther; 12(4); 405-15. ©2013 AACR... - Genotoxic exposure is associated with alterations in glucose uptake and metabolismRixin Zhou
Department of Medicine and the Committee on Cancer Biology, University of Chicago, Illinois 60637, USA
Cancer Res 62:3515-20. 2002..Mitochondrial responses to the resulting rapid decrease in metabolic substrates may play an important role in initiation of apoptotic cell death... - Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancerPaul Ritch
Milwaukee Medical College, Milwaukee, USA
Lung Cancer 52:173-80. 2006..The addition of aprinocarsen to gemcitabine+carboplatin therapy in patients with NSCLC showed moderate activity. However, this combination resulted in severe thrombocytopenia in the majority of patients... - Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignanciesAnatoly Dritschilo
Department of Radiation Medicine, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia 20007
Clin Cancer Res 12:1251-9. 2006..In this dose escalation study, we evaluated the safety of combined liposomal formulation of raf antisense oligonucleotide (LErafAON) and radiation therapy in patients with advanced malignancies... - A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinomaHelen J Ross
Thoracic Oncology Program, Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, 4805 NE Glisan Street, 5F40 Portland, OR 97213, United States
Lung Cancer 54:69-77. 2006..This Phase II, open-label study was conducted to confirm the activity of SGN-15 plus docetaxel in previously treated NSCLC patients... - Bcl-2 and Bcl-xL overexpression inhibits cytochrome c release, activation of multiple caspases, and virus release following coxsackievirus B3 infectionChristopher M Carthy
Department of Pathology and Laboratory Medicine, University of British Columbia-St. Paul's Hospital, The iCAPTUR4E Centre/McDonald Research Laboratories, 1081 Burrard Street, Vancouver, British Columbia, Canada V6Z 1Y6
Virology 313:147-57. 2003..Our data suggest that mitochondrial release of cytochrome c may be an important early event in caspase activation in CVB3 infection, and, as such, may contribute to the loss of host-cell viability and progeny virus release...
Research Grants
- Phase I/II Study of MS-275 and 5-Azacytidine in Patients with Advanced Non-SmallCHARLES RUDIN; Fiscal Year: 2007..If successful, this approach could alter the poor prognosis of individuals with this disease. ..
- GENETIC AND GENOMIC RESPONSES TO DNA DAMAGECHARLES RUDIN; Fiscal Year: 2002..Understanding the molecular basis of the various cellular responses to DNA damage is relevant to the design of both chemopreventative and therapeutic anticancer strategies. ..
- A pharmacogenetic and pharmacodynamic study of erlotinibCHARLES RUDIN; Fiscal Year: 2004..Defining the basis of this toxicity could also promote the development of EGFR-directed agents that may avoid such toxicity or that may be effective in a broader spectrum of cancer patients. ..